Fibrotic outcomes from SARS-CoV-2 virus interstitial pneumonia

Area of Science:

• Pulmonology
• Infectious Diseases
• Radiology

Background:

• COVID-19 pandemic highlighted the need to understand long-term outcomes of SARS-CoV-2 infection.
• Interstitial pneumonia is a significant complication of COVID-19, raising concerns about post-inflammatory fibrotic changes.

Purpose of the Study:

• To evaluate the evolution of COVID-19-related interstitial pneumonia into post-inflammatory fibrotic interstitial disease.
• To assess long-term pulmonary sequelae in patients recovering from SARS-CoV-2 pneumonia.

Main Methods:

• A cohort of 42 patients with SARS-CoV-2 interstitial pneumonia was followed.
• Assessments included inflammation indices, high-resolution computed tomography (CT) chest scans, and functional respiratory tests at multiple time points up to 36 months post-discharge.
• Patients were stratified based on pneumonia severity and respiratory support required (O2 only, non-invasive ventilation, invasive mechanical ventilation).

Main Results:

• 83.3% of patients exhibited residual parenchymal lung disease at 36-month follow-up.
• Severe pneumonia cases and those with more extensive initial CT findings showed a higher rate of residual disease.
• Radiological findings included ground-glass opacities, parenchymal bands, and interstitial thickening suggestive of fibrotic changes.
• Reduced respiratory function and exercise capacity were observed, particularly in patients with severe pneumonia requiring ventilatory support (24% experienced desaturation and reduced exercise tolerance).

Conclusions:

• COVID-19-related interstitial pneumonia can lead to persistent lung disease and fibrotic changes, especially in severe cases.
• Long-term follow-up reveals significant radiological and functional impairments in a substantial proportion of patients.
• Severity of initial pneumonia and inflammatory state correlate with the extent and persistence of lung lesions and functional deficits.